CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 04/13/2021

J. Harris: The above data is the most current available. In the area, active cases are up in LA as well as Smith County, but the hospital Covid census is down, which suggests that the increased cases are the younger folks who have been on break and on holiday. Hopefully, they will not bring home any mutants. 

AREA DATA 13 APRIL FROM NYT:

SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women

“This study found robust secretion of SARS-CoV-2 specific IgA and IgG antibodies in breast milk for 6 weeks after vaccination. IgA secretion was evident as early as 2 weeks after vaccination followed by a spike in IgG after 4 weeks (a week after the second vaccine). A few other studies have shown similar findings in women infected with COVID-19.5 Antibodies found in breast milk of these women showed strong neutralizing effects, suggesting a potential protective effect against infection in the infant.” 

U.S. Calls for Pause on Johnson & Johnson Vaccine After Clotting Cases

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccinatio

Vaccination with ChAdOx1 nCov-19 can result in the rare development of immune thrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thrombocytopenia. 

(J. Harris: The two references above are related to RARE but very real side effects on two vaccines, AstraZenaca and J & J. The J & J is used in the US. Both are based on an adenovirus vaccine, and both are proficient in preventing most Covid as well as limiting the effects of Covid if it does occur. If you have already taken the J & J vaccine, you will have a couple of weeks to worry, but the rare clotting disorder that may well be due to the vaccines, is RARE, RARE, RARE and you are not likely to get it. For now, the use of the J & J will be paused. 

CITED BY HOPKINS

Regeneron Says Antibody Cocktail Prevented Covid When Given as Simple Injection, Not an IV (STAT News) Regeneron Pharmaceuticals said Monday that a single administration of its monoclonal antibody cocktail reduced the risk that volunteers exposed to Covid-19 would develop the disease by 81%. The study enrolled 1,500 healthy volunteers, each of whom shared a home with someone who tested positive for SARS-CoV-2, and randomized them to receive a single dose of its antibody treatment, given subcutaneously as four shots, or placebo. After 29 days, 11 patients in the treatment group developed Covid-19 compared to 59 on placebo. And for the subjects who got Covid-19 despite treatment, their symptoms resolved after one week, compared to three weeks for those on placebo. The results were made public in a press release, and will be published in a scientific journal or presented at a medical meeting at a later date.

LAST BUT NOT LEASED:

42.7 percent of all statistics are made up on the spot.

Eagles may soar, but weasels don’t get sucked into jet engines

***********************************

GIVE US YOUR FEEDBACK.  CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.

Click here to submit feedback.  Let us know what you think.

click here to CLOSE THIS PAGE